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Background: TB/HIV co-infection is a major service challenge in Sub-Saharan Africa. Many countries 
rely on nevirapine-containing fixed dose combinations as the mainstay of ART. The clinical and 
virological significance of the reduction in trough levels of nevirapine (NVP) due to interaction with 
rifampicin is not sufficiently understood.  
Objectives: To compare virological, immunological, and clinical outcomes, as well as drug tolerability, in 
HIV-infected patients who underwent rifampicin-based treatment for tuberculosis concomitantly with 
combination antiretroviral therapy (cART) containing nevirapine versus patients who received cART 
containing efavirenz. 
Methods: Prospective cohort study of all treatment-naïve adults started on cART in Khayelitsha by the 
end of 2005. Survival, virological suppression, CD4 count gain, and liver enzyme changes were 
compared for groups of patients on NVP or EFV, with or without TB treatment.  Multivariate regression 
models were used for analysis. 
Results:  A lower probability of virological suppression at 18 months was associated with starting NVP 
when on TB treatment as compared to NVP alone;  and with NVP when compared to EFV in patients 
not on TB treatment.  No increased risk of failure was found when starting TB therapy whilst on cART.  
Increases in CD4 count were equivalent between the groups.  Severe hepatic events on NVP were few, 
and were not associated with concomitant rifampicin use.  
Conclusions: Hepatic induction reducing NVP levels might be of particular concern when initiating 
cART in patients on TB treatment. The differences in virological suppression between patients on EFV 
and NVP without exposure to TB therapy are an unexpected finding warranting further exploration.  
Concurrent TB treatment in this cohort has not been associated with inferior outcomes.  The lack of 
association between the concurrent use of rifampicin and nevirapine and increases in ALT are 
encouraging. 
 
 
 
 
 
 
 